After discontinuing its only clinical-stage candidate and several preclinical solid tumor programs, ADC Therapeutics announced the closure of its UK research site and 30% workforce reduction. This restructuring focuses resources on approved and prioritized antibody-drug conjugates amid ongoing clinical setbacks, signaling significant operational challenges for the Swiss biopharma firm.